The ultimate opportunity for advancing pharmacy practice Imagine the ultimate alignment of the stars for advancing pharmacy practice. It would ideally include a condition that is highly prevalent, is managed mostly through drug therapy in the community and has many opportunities for improvement. But to move forward, we would need robust, high-level evidence for pharmacist care. And it would need to be cost-effective for our health care system.
We have this already-it's hypertension. Hypertension affects more than 1 billion people worldwide 1,2 (about 23% of the population in Canada 3 ) and is the single leading modifiable risk factor for premature morbidity and mortality in the world. 4 Hypertension is mostly managed in the community and mostly through drug therapy. Rates of control of hypertension are generally quite poor, with about 30% to 90% of patients globally being uncontrolled 2 (that figure is about 35% in Canada and about 40% for those with diabetes in Canada 3 ). There is already robust clinical trial evidence for pharmacist care-Santschi et al. 5 reviewed 39 trials of pharmacist care in hypertension, showing an average reduction of 7.6/3.9 mmHg when a pharmacist is involved compared with usual care. And it's even greater when pharmacists prescribe antihypertensive medications (e.g., the RxACTION study). 6 Indeed, hypertension was one of the model conditions put forward by CPhA to the Council of the Federation's Health Care Innovation Working Group in 2013 and is one of the World Health Organization's 25 by 25 targets (i.e., to reduce hypertension by 25% by 2025, see www .who.int/nmh/publications/ncd-infographic-2014.pdf?ua=1). While you have probably heard rumblings of all this before, what has brought us to the tipping point is the article published in the May/June issue of CPJ by Marra et al. 7 In this article, Dr. Carlo Marra and colleagues conducted an economic evaluation of advanced scope of pharmacy practice in patients with hypertension. 7 Essentially, this means taking the blood pressure reduction demonstrated in the RxACTION study (18.3 mmHg systolic) 6 and modelling the reduction in cardiovascular and renal failure events over a time horizon of 30 years. The results are stunning. Pharmacist care for those with hypertension would decrease almost 500,000 cardiovascular and renal events and result in about 1 million life-years saved! 8 And it would substantially reduce costs to our health care system (in fact, if rolled out to just half of the Canadian population with poorly controlled hypertension, the savings would be $15.7 billion). 8 These are extraordinary findingsalmost unprecedented in health care-better outcomes and lower costs with pharmacist care.
This has not gone unnoticed. Hypertension Canada is the only national nonprofit organization dedicated solely to the prevention and control of hypertension and its complications. 9 In fact, the Hypertension Canada (formerly CHEP) guidelines have recognized the special role of pharmacists since 2010. Hypertension Canada's vision is: "Canadians will have the healthiest and best-managed blood pressure in the world, " and pharmacists are a key strategy to achieving this vision. 9 To this end, Hypertension Canada has involved more than 1500 pharmacies in World Hypertension Week this past May. Pharmacists have also participated in Hypertension Canada's Primary Care Continuing Education days earlier this year. Looking to the near future, Hypertension Canada will be reviewing this new evidence for the role of the pharmacist in hypertension assessment and management. Hypertension Canada will be launching a pharmacist certification program in hypertension management.
What can you do? These benefits to society (and the profession) won't be realized without your participation. Here's how you can help:
• Become a member and volunteer with your pharmacy professional organizations to help them take this forward. They need your help! There is strength in numbers. • Join Hypertension Canada-there are many volunteering opportunities. So, not only are the stars aligning, but perhaps also the universe. We have an unprecedented opportunity and a societal duty to move hypertension care forward. ■ ROss T. Tsuyuki, BsC(PhaRm), PhaRmD, msC, FCshP, FaCC aNgeLique BeRg NaDia a. khaN, mD, msC, FRCP(C)
